Foscarnet-related Hypercalcemia During CMV Treatment in an Infant With SCID: A Case Report and Review of Literature.
Foscarnet is a main treatment for disseminated cytomegalovirus infection in immunocompromised patients. One of its documented side effects is hypocalcemia. Hypercalcemia, in contrast, was described anecdotally before, almost exclusively in adults with human immunodeficiency virus infection or posttransplantation. We describe a case of severe hypercalcemia during foscarnet treatment in an infant with IL-7 Rα deficient severe combined immunodeficiency, resolved after treatment cessation. We speculate that this unusual side effect is caused by foscarnet binding to the inorganic matrix of bone.
*Pediatric Department A §Pediatric Endocrinology Unit, Sheba Medical Center, Edmond and Lily Safra Children's Hospital, Tel Hashomer †Sackler Faculty of Medicine, Tel Aviv University ‡Cancer Research Center, Pediatric Immunology Service, Jeffrey Modell Foundation (JMF) Center, Sheba Medical Center, Tel Aviv University, Tel Aviv, Israel.
Shira
S
Rabinowicz
Raz
R
Somech
Yonatan
Y
Yeshayahu
D001857:Bone Matrix / Q000378:metabolism; D003586:Cytomegalovirus Infections / Q000188:drug therapy*; D017245:Foscarnet / Q000008:administration & dosage* / Q000378:metabolism; D006801:Humans; D006934:Hypercalcemia / Q000139:chemically induced* / Q000209:etiology; D007223:Infant; D053699:Interleukin-7 Receptor alpha Subunit / Q000172:deficiency; D016511:Severe Combined Immunodeficiency / Q000139:chemically induced*
C000620371:IL7R protein, human; D053699:Interleukin-7 Receptor alpha Subunit; D017245:Foscarnet